Avxentyev N A, Davydovskaya M V, Makarova Y V, Frolov M Yu, Klabukova D L
Financial Research Institute, Moscow, Russia.
The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(8):30-36. doi: 10.17116/jnevro202112108130.
To conduct a pharmacoeconomic analysis of using cladribine (in tablets) as a second-line treatment option for adult patients with highly active remitting multiple sclerosis in Russia.
Current treatment practice of highly active multiple sclerosis (natalizumab, fingolimod, alemtuzumab, ocrelizumab) was considered as a comparator for cladribine (in tablets). Clinical and economic study was conducted using the «cost minimization» method. For budget impact analysis cost of using cladribine (in tablets) was compared to the cost of using current treatment practice.
Cladribine in tablets is a cost-saving alternative for treatment of patients with highly active multiple sclerosis compared to the current treatment practice. Within a 4-year period direct medical costs reduction is 2 million RUB (50.1%) per person.
In case of switching the patients, who are currently provided with other disease modifying drugs, to cladribine, in 4 years health budget will save up to 6284 million RUB (50.1%).
对俄罗斯成年高度活动性复发缓解型多发性硬化症患者使用克拉屈滨（片剂）作为二线治疗方案进行药物经济学分析。
将高度活动性多发性硬化症的当前治疗方法（那他珠单抗、芬戈莫德、阿仑单抗、奥瑞珠单抗）作为克拉屈滨（片剂）的对照。采用“成本最小化”方法进行临床和经济学研究。为进行预算影响分析，将使用克拉屈滨（片剂）的成本与使用当前治疗方法的成本进行比较。
与当前治疗方法相比，克拉屈滨片剂是治疗高度活动性多发性硬化症患者的一种节省成本的替代方案。在4年期间，每人直接医疗成本降低200万卢布（50.1%）。
如果目前接受其他疾病修正药物治疗的患者改用克拉屈滨，4年内卫生预算将节省高达6.284亿卢布（50.1%）。
